Susquehanna Fundamental Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-633	Closed	-$264K	–	1212
2022 Q3	$264K	Buy	+633	New	+$316K	﹤0.01%	1194
2022 Q1	$6.49M	Buy	11,525 +10,785	+1,457%	+$6.5M	0.13%	230
2021 Q4	$559K	Sell	740 -9,282	-93%	-$6.95M	0.01%	870
2021 Q3	$7.48M	Buy	10,022 +8,682	+648%	+$6.5M	0.14%	188
2021 Q2	$863K	Sell	1,340 -520	-28%	-$316K	0.02%	915
2021 Q1	$1.06M	Sell	1,860 -6,723	-78%	-$3.98M	0.02%	864
2020 Q4	$5M	Buy	+8,583	New	+$4.89M	0.09%	313

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Susquehanna Fundamental Investments's BIO Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2022, closing a stake of 633 shares — an estimated $264K sold.

Susquehanna Fundamental Investments first reported a position in BIO in Q4 2020 and held it in 7 quarters. The position peaked at $7.48M in Q3 2021. 472 funds tracked by Wall St. Rank hold BIO as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Bio-Rad Laboratories Class A position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 633 Bio-Rad Laboratories Class A shares in Q4 2022, an estimated $264K.
Susquehanna Fundamental Investments first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 7 quarters.
Susquehanna Fundamental Investments's Bio-Rad Laboratories Class A position peaked at $7.48M in Q3 2021.
472 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.